Carcinogenesis, Vol. 21, No. 10, 1851-1858,
October 2000
© 2000 Oxford University Press
Carcinogenesis |
Major inter-species differences in the rates of O-sulphonation and O-glucuronylation of 
-hydroxytamoxifen in vitro: a metabolic disparity protecting human liver from the formation of tamoxifen–DNA adducts
1 Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool L69 3BX and
2 MRC Toxicology Unit, Hodgkin Building, Lancaster Road, Leicester LE1 9HN, UK
Tamoxifen is a hepatic genotoxin in rats and mice but a hepatocarcinogen only in rats. It is not associated with DNA adducts and liver tumours in patients. The proposed major pathway for its bioactivation in rats involves 
-hydroxylation, O-sulphonation and generation of a carbocation that reacts with DNA. Rat liver microsomes catalyse -hydroxylation at ~2- and 4-fold the rate achieved by human and murine liver microsomes, respectively. O-glucuronylation will deactivate -hydroxytamoxifen and compete with sulphonation. Rates of O-sulphonation of -hydroxytamoxifen in hepatic cytosol have been determined by a HPLC assay of substrate-dependent 3'-phosphoadenosine 5'-phosphate production. The rank order of O-glucuronylation in hepatic microsomes was estimated by HPLC–mass spectrometry. The rate of sulphonation of trans--hydroxytamoxifen (25 µM) in cytosol from adult female Sprague–Dawley rats and CD1 mice was 5.3 ± 0.8 and 3.9 ± 0.5 pmol/min/mg protein (mean ± SD, n = 3), respectively. In cytosol fractions from women aged 40–65 years, the rate was 1.1 ± 0.4 pmol/min/mg protein (mean ± SD, n = 6). The Km for trans--hydroxytamoxifen in rat, mouse and human cytosol was 84.6 ± 3.8, 81.4 ± 4.6 and 104.3 ± 5.6 µM (mean ± SD, n = 3), respectively; the corresponding Vmax values were 22.4 ± 3.4, 17.1 ± 3.1 and 6.3 ± 1.9 pmol/min/mg protein. These Km were similar to a value obtained by others using purified rat liver hydroxysteroid sulphotransferase a. Turnover of the cis epimer was too slow for accurate determination of rates. Sulphonation of trans--hydroxytamoxifen in human uterine cytosol was undetectable. The rank order of O-glucuronylation of trans--hydroxy- tamoxifen in liver microsomes was human > > mouse > rat. In combination, lower rates of -hydroxylation and O-sulphonation and a higher rate of O-glucuronylation in human liver would protect patients from the formation of tamoxifen–DNA adducts.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. P. Williams, D. J. Antoine, P. J. Butler, R. Jones, L. Randle, A. Payne, M. Howard, I. Gardner, J. Blagg, and B. K. Park The Metabolism and Toxicity of Furosemide in the Wistar Rat and CD-1 Mouse: a Chemical and Biochemical Definition of the Toxicophore J. Pharmacol. Exp. Ther., September 1, 2007; 322(3): 1208 - 1220. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Brown, E. M. Tompkins, D. J. Boocock, E. A. Martin, P. B. Farmer, K. W. Turteltaub, E. Ubick, D. Hemingway, E. Horner-Glister, and I. N.H. White Tamoxifen Forms DNA Adducts in Human Colon after Administration of a Single [14C]-Labeled Therapeutic Dose Cancer Res., July 15, 2007; 67(14): 6995 - 7002. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. H. Phillips, A. Hewer, M. R. Osborne, K. J. Cole, C. Churchill, and V. M. Arlt Organ specificity of DNA adduct formation by tamoxifen and {alpha}-hydroxytamoxifen in the rat: implications for understanding the mechanism(s) of tamoxifen carcinogenicity and for human risk assessment Mutagenesis, July 1, 2005; 20(4): 297 - 303. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. J. Schild, D. H. Phillips, M. R. Osborne, A. Hewer, F. A. Beland, M. I. Churchwell, K. Brown, M. Gaskell, E. Wright, and M. C. Poirier Hepatic DNA adduct dosimetry in rats fed tamoxifen: a comparison of methods Mutagenesis, March 1, 2005; 20(2): 115 - 124. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. I. Apak and M. W. Duffel INTERACTIONS OF THE STEREOISOMERS OF {alpha}-HYDROXYTAMOXIFEN WITH HUMAN HYDROXYSTEROID SULFOTRANSFERASE SULT2A1 AND RAT HYDROXYSTEROID SULFOTRANSFERASE STA Drug Metab. Dispos., December 1, 2004; 32(12): 1501 - 1508. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Maiti and G. Chen Tamoxifen Induction of Aryl Sulfotransferase and Hydroxysteroid Sulfotransferase in Male and Female Rat Liver and Intestine Drug Metab. Dispos., May 1, 2003; 31(5): 637 - 644. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Boocock, K. Brown, A. H. Gibbs, E. Sanchez, K. W. Turteltaub, and I. N.H. White Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNA Carcinogenesis, November 1, 2002; 23(11): 1897 - 1902. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Strott Sulfonation and Molecular Action Endocr. Rev., October 1, 2002; 23(5): 703 - 732. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kasahara, M. Hashiba, T. Harada, and M. Degawa Change in the gene expression of hepatic tamoxifen-metabolizing enzymes during the process of tamoxifen-induced hepatocarcinogenesis in female rats Carcinogenesis, March 1, 2002; 23(3): 491 - 498. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. R. Ireson, D. J. L. Jones, S. Orr, M. W. H. Coughtrie, D. J. Boocock, M. L. Williams, P. B. Farmer, W. P. Steward, and A. J. Gescher Metabolism of the Cancer Chemopreventive Agent Curcumin in Human and Rat Intestine Cancer Epidemiol. Biomarkers Prev., January 1, 2002; 11(1): 105 - 111. [Abstract] [Full Text]
|
|
|
|
|
|
D. H. Phillips Understanding the genotoxicity of tamoxifen? Carcinogenesis, June 1, 2001; 22(6): 839 - 849. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Elsby, J. L. Maggs, J. Ashby, and B. K. Park Comparison of the Modulatory Effects of Human and Rat Liver Microsomal Metabolism on the Estrogenicity of Bisphenol A: Implications for Extrapolation to Humans J. Pharmacol. Exp. Ther., April 1, 2001; 297(1): 103 - 113. [Abstract] [Full Text]
|
|